ABSTRACT
INTRODUCTION
Inflammatory bowel disease (IBD) encompasses a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract. The major phenotypes of IBD are Crohn's disease (CD) and ulcerative colitis (UC), which are traditionally found at opposite ends of the spectrum.
The relationship between nutrition and IBD is complex and involves several aspects: a) the nutritional status of IBD patients; b) the therapeutic goals of nutritional treatment, including nutritional therapy as support treatment, the induction of remission, and maintenance treatment; c) the type of formula composition used for nutritional treatment in different studies; and d) the dietary modulation of the intestinal immune response in IBD and its potential clinical implications.
Nutritional therapy in IBD is carried out through total parenteral nutrition (TPN) or enteral nutrition (EN), the latter can be administered both via the nasogastric or oral route (1, 2) . Several studies have evaluated the effect of certain modifications to the composition of the parenteral and, in particular, enteral diets, including changes in the content of fats, proteins, carbohydrates, bioactive peptides (e.g. glutamine), growth factors, butyrate, omega-3 fatty acids, and antioxidants.
This article reviews current evidence of the efficacy of nutritional therapy in the treatment of IBD, considering the different types of formula composition studied and the role of dietary factors in the etiopathogenesis of the disease. A literature search was carried out for the period between Nutritional treatment in inflammatory bowel disease. An update 1991 and April, 2012 . We searched the PubMed, Cochrane, and Scopus libraries using the following individual and combined key words: Crohn's disease, ulcerative colitis, diet, dietary intervention, dietary treatment, enteral or parenteral nutrition, inflammatory bowel disease, nutritional therapy, exclusion diet, nutritional status, nutrigenomics, and dietary risk factors. References cited in the articles obtained were also searched in order to identify other potential sources of information. The results were limited to human studies available in English.
NUTRITIONAL STATUS OF IBD PATIENTS
The nutritional status of IBD patients is significantly compromised at different levels. The most important causes of malnutrition are decreased food intake (anorexia, abdominal pain, nausea, vomiting, or restricted diets); the malabsorption of nutrients (reduced absorptive surface due to inflammation, resection, bypass, and fistulae); increased intestinal loss due to gastrointestinal disorders; hypermetabolic states; and drug interactions with corticosteroids, sulfasalazine, immunosuppressants, or antimicrobials (3) .
In the past, protein-energy malnutrition was very common in IBD patients, affecting 70-80% of hospitalized patients (4) . Malnutrition was more common in CD than in UC patients, with an incidence ranging from 25% to 80% (5-7), especially during remission of the disease. This effect could be related to the significant influence of small bowel involvement in patient body weight. The prevalence of protein-energy malnutrition has decreased over the years and recent studies have shown that most adult IBD patients have good nutritional status, although they have significant abnormalities in body composition and some specific nutritional deficiencies (8) .
However, protein-energy malnutrition remains one of the major complications in children with IBD. Weight loss is present at diagnosis in up to 90% of children (9) . Growth failure at the time of diagnosis has been reported in 23-88% of children with CD, being less common in UC patients (10) . About 30-40% of children affected continue to have severe linear growth impairment during the course of the disease, with a final body height below the 5 th percentile in 7-30% of patients. This stems from the fact that CD usually starts at a younger age, impairing growth velocity (11) .
THERAPEUTIC GOALS OF NUTRITIONAL TREATMENT IN IBD PATIENTS

Nutritional support therapy
It is important to emphasize that undernutrition has a negative impact on the clinical course, rate of postoperative complications (especially anastomotic breakdown), and mortality (sepsis, methicillin-resistant Staphylococcus aureus, pneumonia, and other resistant infections) in IBD patients (12, 13) . Moreover, undernutrition causes humoral and cellular immunodeficiency, leading to impairment of the mucosal barrier and a greater risk of infection by bacterial translocation (14) . Taking all this into account, one of the most important goals of nutritional therapy should be to prevent and treat undernutrition, improving the growth and development of children and adolescents using TPN, EN, or by correcting micronutrient deficiency (1, 2) .
TPN seems to have a limited role as supportive adjunct therapy in the management of IBD. Still, it may be indicated in some restricted cases, such as in an obstructed bowel that is not amenable to feeding tube placement beyond the obstruction, a short bowel resulting in severe malabsorption or fluid and electrolyte loss that cannot be managed enterally, severe dysmotility in which enteral feeding is impossible, a leaking intestine from high-output intestinal fistula or surgical anastomotic breakdown, in patients intolerant to EN whose feeding cannot be maintained orally, when there is an inability to access the gut for enteral feeding, and in patients undergoing IBD-related bowel surgery in the perioperative period (1, 6, (15) (16) (17) (18) .
In addition to the fact that it delivers normal food, EN (with oral nutritional supplements or tube feeding) may be more useful than TPN in the management of undernourished patients with IBD. If the gut can be used safely, EN is actually the preferred feeding method for CD or UC patients needing nutritional support. The advantages of EN include its stimulatory effects on gastrointestinal structure and function as well as its reduced cost compared to parenteral feeding. Oral nutritional supplements (with 500-600 kcal/day) and/or tube feeding improve the nutritional status in adults and especially in children with CD (19) (20) (21) . In fact, 50% of growth-retarded CD patients cannot regain their body weight through medical therapy alone and must use enteral tube feeding (22) . To date, no definitive data has been published on supplementation with oral nutritional supplements in UC patients, who should undergo enteral tube feeding only in exceptional cases (e.g. severe UC without toxic megacolon, colonic perforation or massive colonic bleeding).
Micronutrient deficiency occurs more often in IBD patients with prolonged periods of diarrhea, vomiting, and increased fistula output (23, 24) . Even when patients seem to be well-nourished, they may show vitamin or mineral deficiencies that need therapeutic correction (lower serum concentrations of water-soluble vitamins, plasma antioxidant vitamins, vitamin E, K, 25(OH)-vitamin D, iron, and other micronutrients). In particular, vitamin D deficiency is common in CD patients, with levels of parathyroid hormone correlating to bone mineral density in these patients (25, 26) . Indeed, a randomized controlled study concluded that long-term oral vitamin D supplementation could prevent bone loss in CD patients (27) . Finally, it is becoming increasingly apparent that it may have a central role in immune responses and intestinal inflammation (28).
Folic acid deficiency observed in half the number of patients with IBD might be due to difficulties in swallow- ing (low-fiber diets), poor absorption or competitive inhibition by certain treatments, such as sulphasalazine or methotrexate (29) . The absence of folic acid has been related to the increased risk of colitis-associated carcinogenesis (30, 31) , as it has a protective effect against high-grade dysplasia and cancer in patients with long-term UC (32, 33) . Folate deficiency is also linked to the increased incidence of arterial and venous thromboembolic events observed in CD and UC (34) , due to hyperhomocysteinemia, a wellknown inducer of hypercoagulability states. Both folic acid and vitamin B12 are essential co-factors in the metabolic route of homocysteine-methionine. Between 20% and 60% of patients with CD and terminal ileitis are deficient in vitamin B12 (14) .
Nutritional induction therapy
Available data so far show that while artificial nutrition seems to play a primary role in the management of patients with active CD, it does not have a primary therapeutic effect in active UC and does not induce clinical remission of this type of IBD.
The use of TPN in the management of active CD is based on theoretical advantages including bowel rest, which could reduce the motor and transport functions of the diseased bowel; reduction of antigenic stimulation, which could eliminate the immunological response to food favored by the presence of impaired intestinal permeability; and stimulation of protein synthesis, which could lead to cell renewal and mucosal healing in the intestine (35) . Nevertheless, few controlled clinical trials have been conducted on the use of TPN to induce remission in active CD. The remission rate three months after starting TPN varied from 20% to 79%, depending on the patient population, length of TPN administration, definitions of remission or recurrence, and concomitant use of medication (36) . TPN has also been shown to achieve fistula healing in 43-63% of patients, accompanied by disease activity reduction and weight gain (37, 38) . However, TPN does not seem to be better than EN or steroids in terms of efficacy (39) . TPN was also associated with an increased risk of adverse events such as sepsis and cholestatic liver disease. All these findings indicate that TPN should not be used as a primary treatment in IBD patients unless they are intolerant to EN and/or steroids (2), but the high efficacy of immunomodulatory and biological drugs advise us against NPT.
Several studies have demonstrated the efficacy of EN in active CD. While EN's mechanisms of action remain unknown, several hypotheses have been proposed, including the ability of nutrients to modulate the commensal microflora and the intestinal immune response by reducing antigen exposure. In fact, EN seems to exert a direct antiinflammatory effect on the intestinal mucosa by reducing IL-6 production and increasing insulin-like growth factor (IGF)-1 production (40). To date, no randomized controlled trials (RCTs) of EN versus a placebo have been conducted (41) . However, EN has been proven to be effective in the treatment of the acute phase of CD, achieving remission rates from 20% to 84.2% regardless of disease location. The variability in these results may stem from differences among study populations, administration protocols and outcome assessments.
There are some important differences between child and adult CD regarding the use of EN as induction therapy. Four meta-analyses and a recent Cochrane literature review showed that steroid treatment is more effective than EN in treating adult CD (42) (43) (44) (45) (46) . In this population, then, EN should not be indicated as a sole therapy unless treatment with corticosteroids is not feasible, as is the case of refractoriness, dependency, intolerance, or refusal of steroid treatment, as well as in patients at high-risk for osteoporosis (1) . It is also important to underscore that relapse rates after EN treatment are high (50-90% at 12 months) in studies carried out in adults (47) . In any case, more studies are needed to evaluate the treatment's long-term outcome. Combined therapy (EN and steroids) could be indicated both in undernourished adult patients and in patients with inflammatory intestinal stenosis (1) .
In contrast, EN is considered a good first-line therapy for active CD in children, as it reduces both the need for corticosteroids and abdominal pain due to intestinal stenosis. It has also been demonstrated to cause mucosal healing and improve quality of life (48, 49) . Furthermore, the RCTs published to date have shown no differences in terms of efficacy between EN and corticosteroids in pediatric patients (50); indeed, EN as a sole therapy exhibited higher efficacy (51) regardless of the formula composition used (52) . The beneficial effects of EN on growth and rapid nutritional restitution, along with the reduced number of adverse effects compared to corticosteroid therapy, are particularly significant in children, especially because the use of corticosteroids in this population increases the risk of permanent growth failure, causing 20-30% of chronically treated children to reach adulthood with an abnormally short stature. However, due to the limited number of retrospective studies available (53, 54) , questions remain regarding the utility of EN in pediatric CD. For example, the influence of disease location on patient response to EN requires further evaluation (47, 55) as does the relapse rate after initial treatment with EN in long-term outcome studies.
Nutritional maintenance therapy
Studies evaluating the potential role of nutritional treatment in maintaining clinical remission in IBD patients are scarce. This is understandable in the case of TPN, which is impractical for remission maintenance in CD and UC and therefore not recommended for this indication (2) . As a result, no studies evaluating the efficacy of TPN in maintaining CD or UC remission have been published. In the case of EN, only one study has shown that during the fol-low-up period, CD patients in whom remission was induced by parenteral nutrition presented lower recurrence rates if they were kept on EN compared to those who were not (56) . Indeed, available evidence suggests that supplementary EN may be effective as an alternative or adjunct therapy for maintaining remission in adult CD patients (57) (62) . However, in order to confirm these findings, more extensive well-powered studies are needed, especially trials comparing EN with azathioprine and infliximab, which are known to be effective in maintaining remission in CD patients. Unfortunately, the prospective studies that have been conducted to date evaluating the role of EN in maintaining remission in pediatric CD are very limited, making it impossible to reach a conclusion concerning general guidelines on this issue. With regard to UC patients, EN is not recommended for maintaining remission as no clear data exist on the effect of disease-specific formula compositions or nutritional therapy for this purpose (1,2).
TYPES OF FORMULA COMPOSITION FOR NUTRITIONAL TREATMENT
Different types of formula composition have been used in studies evaluating the efficacy of nutritional therapy in IBD patients through either enteral or parenteral administration.
Protein sources
Based on the nitrogen source used, EN can be differentiated between: a) polymeric diets that provide nitrogen in the form of whole protein derived from milk, meat, eggs, or soya, along with carbohydrates such as hydrolysates of starch; b) semi-elemental diets (oligopeptides) made by protein hydrolysis to produce a mean peptide chain length of four or five amino acids, which is too short for antigen recognition or presentation; and c) elemental diets (amino acid-based) containing nutrients in simple forms (e.g. amino acids, simple carbohydrates, fats, vitamins, and minerals) that require little or no digestion prior to absorption. These different protein sources can influence the antigen recognition or presentation process and induce or maintain chronic intestinal inflammation. However, a recent meta-analysis showed no difference in efficacy when different formula compositions (polymeric, semi-elemental, or elemental diets) were used to induce remission in CD patients (60) . In particular, statistically significant differences were found neither on the basis of the nitrogen source of the diet (elemental, semi-elemental, or polymeric diets) nor on the basis of different protein sources. This leads to the tentative conclusion that protein type does not influence the effectiveness of EN. In light of these findings, polymeric diets should be preferred, as they are less expensive and more palatable than their elemental or semi-elemental counterparts.
Glutamine supplementation
Glutamine is an essential amino acid with trophic effects on the intestinal mucosa. Glutamine-supplemented food seems to minimize the impairment of intestinal permeability, protect against intestinal mucosal atrophy, and improve nitrogen balance (63) . In animal models, glutamine supplementation reduces intestinal damage and improves disease behavior. Several RCTs have been conducted to evaluate the efficacy of glutamine supplementation in enteral or parenteral nutrition treatment in humans (64-66); however, none have been able to demonstrate any additional benefits for the glutamine-supplemented groups.
Fat composition
Several different formula compositions have been studied to evaluate the influence of the quantity and type of fat (fish oil or short chain fatty acids) on the outcome of IBD patients, particularly with regard to CD. The use of diets with a very low fat content (0.6%-1.3% of total calories) has been associated with good results in comparison to diets with a very high fat content (12%-30% of total calories), particularly in the presence of large amounts of linoleic acid (67) (68) (69) . While an non-significant trend favoring very low fat and/or very low long-chain triglyceride content was demonstrated in CD patients in a recent Cochrane Review, larger trials are needed to explore the significance of this finding (64) .
The benefits of fish oil (n-3 fatty acids) in treating inflammatory diseases such as psoriasis and rheumatoid arthritis have already been demonstrated. Experimental models of dextran sulfate sodium-induced colitis also support a positive role for n-3 fatty acids supplementation (70) . Likewise, in patients with IBD, fish oil supplementation was found to reduce both inflammation and the necessary dosage of anti-inflammatory drugs while promoting weight gain.
Several trials evaluated the efficacy of oral n-3 fatty acid supplements to maintain remission in CD and UC patients. A recent meta-analysis concluded that n-3 fatty acids may be effective for remission maintenance in CD patients when administered as enteric coated capsules, but showed no benefits in UC patients (71) . In any case, the data are insufficient for recommending their routine use (1) . No data exist to date on the efficacy of administering n-3 fatty acid supplements via the parenteral route in humans.
Short-chain fatty acids (SCFA) such as butyrate serve as an energy source for colonocytes; a reduction in the levels of these substances has been proposed as a possible mechanism in the pathogenesis of IBD. Several studies evaluating the efficacy of topical administration of butyrate instead of corticosteroids or mesalazine to induce remission in UC patients have found a comparable remission rate (72) . The efficacy of using a different administration route (parenteral or enteral) has not yet been established, nor has this topical treatment been proven effective in CD patients with colonic localization.
Carbohydrate composition
It has been suggested that a diet high in carbohydrates promotes the development of CD. Two studies evaluated a specific carbohydrate diet limiting complex carbohydrates (disaccharides and polysaccharides) and eliminating refined sugar altogether (73, 74) , but the effect of a low carbohydrate diet on the clinical course of IBD has yet to be definitively demonstrated.
Growth factors
The addition of bioactive peptides to enteral diet formulas may be beneficial due to their specific growth factor effects and anti-inflammatory actions. Three uncontrolled studies examined the value of a transforming growth factor-β 2 (TGF-β 2 )-enriched formula in pediatric CD patients (75) (76) (77) . All the study subjects received the TGF-β 2 diet for 8 weeks as their sole nutrition source, followed by a 4-week period of controlled reintroduction of normal food. The TGF-β 2 diet was effective in inducing remission (79%) and mucosal healing while reducing the levels of inflammatory markers (erythrocyte sedimentation rate and C-reactive protein). However, the relapse rate was high following remission achieved through nutritional therapy and only one-third of the children agreed to use it. So far, no studies have addressed the role of polymeric diets enriched with TGF-β 2 as adjuvant therapy in achieving and maintaining IBD remission.
Exclusion diet
Several studies have shown that food sensitivity occurs in some CD patients. The most common intolerances observed were against cereals, dairy products, and yeast (78) . However, food intolerance is not as frequent in CD patients as claimed by several previous studies and its occurrence and intensity are variable (79) . While some studies have suggested that exclusion diets based on daily reintroduction of a single food type could be a useful intervention in active CD, one published study showed high relapse rates (62%) after 2 years (78, 80) . In fact, food sensitivity is of such insignificant importance that it does not warrant putting all patients through the inconvenience of elimination diets.
Several digestive disorders affecting the small bowel, including CD, associate an increased intestinal permeability, which lead to detection of increased serum levels of immune complexes of IgE and IgG anti-IgE autoantibodies, when compared to healthy controls (81, 82) . However, autoimmune type I allergy to cellular or diet constituents does not seem to be of significance for IBD (83) . In contrast, nutritional intervention based on circulating IgG antibodies against food antigens showed effects with respect to stool frequency in the sole published study assessing this intervention (84) . Any case, the mechanisms by which IgG antibodies might contribute to disease activity remain to be elucidated.
In conclusion, the aforementioned modifications to enteral diets, elemental diets, or general diets have not yet been proven to have any advantage over standard polymeric diets. Further well-powered studies are needed to evaluate specific formula compositions such as growth factor-enriched diets.
DIETARY MODULATION OF THE INTESTINAL INFLAMMATORY RESPONSE IN IBD AND FUTURE CLINICAL IMPLICATIONS
While the etiology of IBD remains unknown, it has been suggested that it entails enhanced systemic and mucosal immunological reactivity against gut bacterial antigens resulting from complex interactions between the environment and a patient's genetic makeup (85) . This immune reactivity seems to be due to a "loss of tolerance" to autologous enteric flora, resulting in an inappropriate immune response, which in turn leads to the development of a chronic inflammatory process in the intestinal mucosa. In fact, under normal circumstances there are complex interactions between commensal intestinal bacteria, dietary antigens, and the immune system that regulate the maintenance of immune tolerance that seems to be impaired in IBD patients (85, 86) . Alteration of the composition and function of intestinal micobiota could lead to increased stimulation of the intestinal immune system, epithelial dysfunction and greater permeability of the mucosa, and accordingly, the correct characterization of the components of this microflora and the definition of their functions are vital in order to consider probiotic treatment for IBD (87, 88) . Probiotics have shown to be as effective as mesalazine in preventing relapses in patients with UC and in the treatment of pouchitis. Efforts have also been made to identify dietary components (prebiotics) which are capable of regulating the bacterial composition, or which have a trophic effect on the intestinal epithelium. In fact, shortchain fatty acids (butyrate, propionate and lactate) result from the fermentation of fiber by bacterial species in the colon (Bifidobacterium, Eubacterium and Lactobacillus), which promote the good functioning of the mucosa (89) , as demonstrated in patients with UC (90, 91) .
As a source of luminal antigens, the diet is an important factor in the immunopathogenesis of IBD, but whether it plays a primary role in the etiology of IBD or a secondary role in maintaining intestinal inflammation has yet to be definitively established (Fig. 1) .
That being said, there is evidence to suggest that dietary factors may play a primary role in the etiology of IBD. Since the mid-20 th century, the incidence of IBD in general and CD in particular has risen in Western Europe and North America from being a rare condition to one that affects up to 0.2% of the population (92) . This rise in the incidence and prevalence of IBD has paralleled the social and economic development of the affected populations; the adoption of this "Western lifestyle" has included changes in our daily lives, including our dietary intake (93). Several dietary factors have been documented as being associated with CD pathogenesis, such as the quantity and quality of fat intake; fast food ingestion; and total protein, energy, and sugar intake (94) . However, the validity of these findings remains uncertain as they have not been reproduced; moreover, conflicting results have been reported.
The FODMAP hypothesis
Some evidence suggests that several dietary factors such as poorly absorbed short-chain carbohydrates and polyols (known as FODMAPs -fermentable oligo-, di-, and monosaccharides and polyols) may play a role in the etiopathogenesis of CD. The common dietary sources of FODMAPs are fructose, fructans, lactose, polyols, and galactooligosaccharides. They all seem to increase intestinal permeability, which is a predisposing factor to the development of CD in genetically susceptible hosts. The FODMAP hypothesis may thus help explain the etiopathogenesis of CD (94) in that intestinal barrier inefficiency could lead to increased mucosal exposure to luminal pro-inflammatory molecules and micro-organisms and to subsequent potential modulation of mucosal immune responsiveness (95) . There are three main lines of evidence for the involvement of FODMAPs in the pathogenesis of CD:
1. The intake of FODMAPs is increasing in Western societies; 2. The association between an increased intake of sugars and the development of CD; 3. Excessive intake of FODMAPs creates conditions in the bowel that predispose it to CD such as bacterial overgrowth in the small bowel that increases intestinal permeability, luminal changes in the colon that induce epithelial irritation or injury (distension, surfactant activity, and organic acid production), and the induction of selective bacterial proliferation as a prebiotic effect. Taken together, these findings could constitute a target for improving symptoms and reducing current reliance on drug therapy. Recently, exclusion of FODMAPS from the diet has been shown to improve functional gut symptoms in patients with IBD (96) . However, further studies are required.
Exogenous microparticle hypothesis
Another dietary factor that seems to be implicated in the etiopathogenesis of IBD and particularly that of CD is exogenous dietary microparticles (97) . These are defined as non-biological particles of the gastrointestinal lumen with an appropriate size and shape which are taken up by mucosal phagocytes. They appear to be almost exclusively food additives, pharmaceuticals, and toothpaste (aluminosilicates, titanium dioxide, and non-aluminum containing silicates). These exogenous microparticles first absorb certain antigenic luminal materials such as pathogen-associated molecular patterns (PAMPs) and then carry these PAMPs (lipopolysaccharides) to the intestinal tissue via M-cells. In this way, the microparticles seem to establish abnormal immune responsiveness by inducing intestinal immune activity and reducing the physiological immune tolerance of the intestinal mucosa. In fact, some data show that microparticle-conjugates/ agglomerates may exacerbate inflammation in the permeable and hyperresponsive gut of patients with IBD. A pilot study showed that the withdrawal of microparticles from the diet of CD patients was associated with an improvement in symptoms (98) . However, a large multi-centre, double-blind trial found no effect on disease activity (99). In conclusion, the role and possible clinical implication of microparticles in IBD remains elusive.
Nutrigenomics and IBD
Considering recent findings concerning the implication of certain genetic mutations in the pathogenesis of IBD, current nutrigenetic and nutrigenomic approaches are worth noting (100, 101) . Dietary components can alter certain types of gene expression under a normal and variable genetic status to thus become either risk or protective factors for disease development (101) . For example, multidrug resistance 1 (MDR1) is a probable IBD susceptibility gene that encodes a P-glycoprotein (170 kDa). It is vulnerable to inhibition, activation, or induction by various herbal constituents. In fact, while curcumin, ginsenosides, and piperine were all found to inhibit P-glycoprotein, some catechins from green tea were found to be activators of P-glycoprotein-mediated drug transport (102) . Furthermore, nutrigenomic approaches utilize knowledge about the genes involved in disease susceptibility in order to design diets that may potentially overcome the disorder. Some studies developed a specific cell-based assay to test the ability of food components or extracts to overcome the functional effects of certain variant SNPs that may be important in IBD (NOD2 3020insC) (103) . These approaches could lead clinicians to develop a personalized nutritional prescription based on individual genetic variations to address phenotype modifications in IBD patients. However, the role of nutrient-gene interaction in the treatment of IBD patients remains to be established and must be addressed in future clinical studies.
CONCLUSION AND WAY FORWARD
Nutritional therapies can be divided into support nutritional therapy and primary nutritional therapy to induce and maintain remission. Up until now, the use of nutritional treatment as primary therapy has been controversial and the results are less impressive than those achieved using corticosteroid therapy in adult IBD patients, although there is some evidence of its usefulness in the maintenance of remission in adult CD patients. In contrast, nutritional therapy is considered to be a first-line therapy for active CD in children, causing mucosal healing and demonstrating an efficacy equal to that of steroids.
At present there are no universally accepted recommendations on whether one specific type of formula composition should be routinely used over another. Well-powered studies are thus needed to evaluate the efficacy of formulas enriched with active biological factors such as TGF-β 2 which can directly influence the intestinal immune response by restoring the physiological tolerance of the intestinal mucosa. In the future, research on these formula compositions should be developed in order to evaluate their role as primary or adjunctive treatments.
Nutritional therapy has been used in IBD with various individual response results. While the role of nutrient-gene interaction remains unclear in IBD patients, it is important to emphasize that diet is a factor which is always present in the management of IBD, either as conventional food intake or specific nutritional therapy. In light of currently available data, future research will have to consider the potential role of nutrient-gene interaction in drug trials and specific dietary formula compositions.
Finally, emerging knowledge about the etiopathogenesis of IBD provides an important opportunity to discover a potential new role for dietary factors in order to develop new formula compositions and identify new dietary risk factors. This should contribute to a fruitful relationship between clinical and basic scientific approaches in the management of IBD patients.
